CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 13 enrolled
Drug / intervention
G-Pen Mini™ (glucagon injection)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02081014
NCT02081014Phase 2Completed
CompareCT.gov

A Randomized, Phase 2a, Blinded, 3-Way Crossover Dose-Ranging Study With G-Pen Mini™ (Glucagon Injection) to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Type 1 Diabetes Mellitus (T1DM)

Xeris Pharmaceuticals·interventional·Posted Mar 7, 2014·Updated Apr 5, 2018

In Brief

A Phase 2 clinical trial evaluating G-Pen Mini™ (glucagon injection) for Hypoglycemia. Completed, enrolled 13 participants across 1 site.

Detailed Summary

The purpose of the study is to demonstrate that mini-doses of stable liquid glucagon (G-Pen Mini) produced by Xeris Pharmaceuticals are safe and effective as a treatment for mild to moderate hypoglycemia, a complication of diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypoglycemia
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Emissary International LLC

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 7, 2014
Enrollment StartMar 1, 2014
Primary CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 12.3 years ago

Interventions

G-Pen Mini™ (glucagon injection)drug

stable, pre-mixed, liquid glucagon for subcutaneous injection